Lexaria Bioscience (LEXX) provides this update on Human Pilot Study #7 that will evaluate two oral DehydraTECH-semaglutide compositions against Novo Nordisk’s (NVO) commercially available Wegovy tablets. Submissions have now been entered to formally request the required ethics approval from an independent review board. Final laboratory tablet composition work and commercial-scale manufacturing for the DHT-sema test articles for the Study have been completed with third-party independent lab quality-control testing of such test articles currently underway. It is anticipated that receipt of ethics approval, completion of QC testing and packaging of the qualified test articles will occur by early June.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria Bioscience extends material transfer agreement with pharma company
- Lexaria Bioscience launches new study to examine next-gen GLP-1 drugs
- Lexaria Bioscience provides update on GLP-1 oral pill market
- Lexaria Launches New GLP-1 Study to Expand Drug Delivery IP
- Lexaria Bioscience engages CRO for 2026 GLP-1-A26-1 study